APA (7th ed.) Citation

A, M., P, G., SS, K. D., P, M., A, J., K, G., . . . GM, V. (2023). Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 77(10), 1460. https://doi.org/10.1093/cid/ciad401

Chicago Style (17th ed.) Citation

A, Manesh, et al. "Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 77, no. 10 (2023): 1460. https://doi.org/10.1093/cid/ciad401.

MLA (9th ed.) Citation

A, Manesh, et al. "Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 77, no. 10, 2023, p. 1460, https://doi.org/10.1093/cid/ciad401.